The estimated Net Worth of Edward A Ogunro is at least $380 Mille dollars as of 24 November 2009. Edward Ogunro owns over 1,000 units of Luminex Corp stock worth over $200,634 and over the last 15 years he sold LMNX stock worth over $0. In addition, he makes $178,984 as Lead Independent Director at Luminex Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Edward Ogunro LMNX stock SEC Form 4 insiders trading
Edward has made over 1 trades of the Luminex Corp stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of LMNX stock worth $13,780 on 24 November 2009.
The largest trade he's ever made was buying 1,000 units of Luminex Corp stock on 24 November 2009 worth over $13,780. On average, Edward trades about 67 units every 0 days since 2009. As of 24 November 2009 he still owns at least 5,424 units of Luminex Corp stock.
You can see the complete history of Edward Ogunro stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Edward Ogunro biography
Dr. Edward A. Ogunro Ph.D. serves as Lead Independent Director of the Company. Dr. Ogunro has served as a member of our Board of Directors since May 2009. Dr. Ogunro served as senior vice president, R&D and medical affairs and chief scientific officer at Hospira Inc., a global specialty pharmaceutical and medication delivery company, from April 2004 until December 2007. Prior to Abbott Laboratories’ (“Abbott”), a global, broad-based healthcare company, spin-off of Hospira in 2004, Dr. Ogunro served in a number of leadership positions for over 20 years with Abbott, primarily in Abbott’s Diagnostics Division, and most recently served as corporate vice president, R&D, medical and regulatory affairs in Abbott’s Hospital Products Division. He held numerous other positions with Abbott, including program director for AxSym and divisional vice president for Abbott’s Immunodiagnostics and Chemistry R&D Organization. Dr. Ogunro served on the board of directors of the Myeloproliferative Neoplasms Research Foundation (a not for profit organization). Previously, Dr. Ogunro pursued postdoctoral studies and served as an assistant professor at Northwestern University Medical School in Chicago from 1977 to 1982. Dr. Ogunro holds a B.S. in Physiology and Biochemistry from Reading University and a Ph.D. in Biochemistry from London University.
What is the salary of Edward Ogunro?
As the Lead Independent Director of Luminex Corp, the total compensation of Edward Ogunro at Luminex Corp is $178,984. There are 7 executives at Luminex Corp getting paid more, with Nachum Shamir having the highest compensation of $3,362,140.
How old is Edward Ogunro?
Edward Ogunro is 67, he's been the Lead Independent Director of Luminex Corp since 2020. There are 1 older and 12 younger executives at Luminex Corp. The oldest executive at Luminex Corp is Thomas Erickson, 69, who is the Independent Director.
What's Edward Ogunro's mailing address?
Edward's mailing address filed with the SEC is 12212 TECHNOLOGY BOULEVARD, , AUSTIN, TX, 78727.
Insiders trading at Luminex Corp
Over the last 21 years, insiders at Luminex Corp have traded over $55,627,864 worth of Luminex Corp stock and bought 685,936 units worth $10,423,148 . The most active insiders traders include G Walter Ii Loewenbaum, Douglas C Bryant e Laurence E Hirsch. On average, Luminex Corp executives and independent directors trade stock every 26 days with the average trade being worth of $888,944. The most recent stock trade was executed by Harriss T Currie on 1 March 2021, trading 5,325 units of LMNX stock currently worth $97,235.
What does Luminex Corp do?
The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.
What does Luminex Corp's logo look like?
Complete history of Edward Ogunro stock trades at Luminex Corp
Luminex Corp executives and stock owners
Luminex Corp executives and other stock owners filed with the SEC include:
-
Nachum Shamir,
President, Chief Executive Officer, Director -
Harriss Currie,
Chief Financial Officer, Senior Vice President - Finance, Treasurer -
Richard Rew,
Senior Vice President, General Counsel and Corporate Secretary -
Todd Bennett,
Senior Vice President - Global Sales and Customer Operations -
Randall Myers,
Senior Vice President - Global Manufacturing and Quality -
Kenneth Samet,
Independent Director -
Kevin McNamara,
Independent Director -
Jimmy Kever,
Independent Director -
Edward Ogunro,
Lead Independent Director -
Thomas Erickson,
Independent Director -
Stephen Eck,
Independent Director -
Dijuana Lewis,
Independent Director -
Eric Shapiro,
Senior Vice President - Global Marketing -
Nancy Fairchild,
Senior Vice President - Human Resources -
Chuck Collins,
Senior Vice President - Research and Development -
Robert J Cresci,
Director -
Tadd S. Lazarus,
SVP, Chief Medical Officer -
Jay B Johnston,
Director -
Russell S Bradley,
VP, Strategic Planning and Bus -
G Walter Ii Loewenbaum,
Director -
Jim D Kever,
Director -
Gregory J Gosch,
Vice President - Marketing -
Charles J. Collins,
SR VP, R&D - US -
John C Carrano,
VP, Research & Development -
J Stark Phd Thompson,
Director -
Douglas C Bryant,
EVP, Chief Operating Officer -
James W Jacobson,
VP, Research & Development -
Oliver H Meek,
VP, Manufacturing -
Randel S Martin,
VP, Marketing/Sales -
Kristi M Richburg,
Controller -
G Walter Ii Loewenbaum,
Director -
C Thomas Caskey,
Director -
Laurence E Hirsch,
Director -
Fred C Jr Goad,
Director -
Jeremy K Bridge Cook,
VP, Luminex Molecular Diagn -
Michael F Pintek,
SVP Operations -
Patrick J Balthrop,
President, Chief Exec. Officer -
Timothy R Dehne,
VP, Systems R&D -
David S Reiter,
General Counsel & Secretary -
Gerard Vaillant,
Director